Researchers found that commonly used kidney function tests, such as estimated GFR, significantly underestimate chronic kidney disease in patients with cancer. This discrepancy can lead to inadequate treatment decisions, including dose adjustments for anticancer therapy. The study suggests that errors in GFR estimation may contribute to...
US-Mexico border counties experience disproportionately elevated rates of death from chronic kidney disease (CKD), with reduced availability of nephrologists. The findings highlight a growing kidney health disparity, with counties having the lowest nephrologist density having substantially higher mortality rates.
The Phase 2 BESTOW trial shows that tegoprubart preserves kidney function and improves quality of life in kidney transplant recipients. Tegoprubart-treated patients had greater kidney function benefits and improved health-related quality of life compared to tacrolimus-treated patients.
A new study links social determinants of health to kidney failure risk among critical illness survivors, highlighting racial and socioeconomic disparities. Neighborhood-level socioeconomic disadvantage is associated with an increased risk of kidney failure, particularly among residents of moderately and highly deprived neighborhoods.
A clinical decision support tool, Treat CKD, has been developed to improve the diagnosis and treatment of chronic kidney disease (CKD) in primary care. The tool accurately confirms Kidney Disease: Improving Global Outcomes-based CKD risk classification and provides guideline-concordant treatment recommendations.
A clinical trial found that adding potassium binder sodium zirconium cyclosilicate (SZC) improved quality of life and reduced pre-dialysis serum potassium levels in patients on maintenance hemodialysis. SZC also increased fruit intake without increasing total dietary potassium intake.
A recent clinical trial found that dietary acid reduction with fruits and vegetables was associated with more favorable long-term clinical outcomes and health care utilization than standard treatment with sodium bicarbonate or usual care. Participants who received fruits and vegetables had fewer hospitalizations, emergency department v...
A prospective study found that the ROCKY standardized protocol is safe for high-risk patients, with a low rate of severe complications and no procedure-related deaths. The protocol's implementation may broaden access to kidney biopsy for vulnerable patient populations.
Multiple high-impact phase 3 clinical trials demonstrate significant improvements in kidney health, offering new treatments for patients. These trials have the potential to revolutionize kidney-related medical care and will be presented at the American Society of Nephrology Kidney Week 2026.
A Texas-based transitional dialysis program decreased emergency department visits and hospital admissions by providing outpatient dialysis access to uninsured patients. The program, piloted in Travis County, resulted in most patients obtaining permanent dialysis access within a year.
A global study found stable AKI-related mortality rates globally, but with differing patterns indicating a rise in mortality among older adults and high-income countries. The study also revealed declining mortality rates in low- and middle-income countries due to improvements in healthcare access.
A quality improvement intervention implemented at a Thai hospital resulted in a significant reduction of metformin-associated lactic acidosis (MALA) deaths. The protocol included immediate dialysis and increased awareness, reducing mortality rates by 13.9% and care variation.
A prediction model estimates individualized survival probabilities with conservative non-dialytic management versus dialysis transition in patients with advanced chronic kidney disease. The study found certain factors, including older age and higher albuminuria levels, linked to higher mortality risk.
A new study suggests that including a patient's 2-year risk of progression to kidney failure as a decision-making tool can improve patient outcomes and reduce racial disparities in kidney transplantation. The study found that this approach prioritizes individualized care and could benefit younger patients with chronic kidney disease.
High-impact clinical trials are generating promising results for improving kidney health, according to recent studies. These trials are paving the way for innovative treatments and therapies to combat kidney diseases.
A recent analysis of the SPRINT trial suggests that nearly all adults with CKD would experience benefits outweighing the harms from a systolic blood pressure target <120 mm Hg. The study found greater net benefits for more advanced CKD groups, supporting KDIGO guidelines.
Researchers found that dual SGLT1/2 inhibition reduces mean arterial pressure and attenuates kidney injury more effectively than selective SGLT2 inhibition. Sotagliflozin also improves urinary sodium, chloride excretion, and fractional glucose excretion.
New research reveals that primary glomerular diseases in children and young adults may experience faster kidney function decline than older patients. Pediatric patients with biopsy-diagnosis of MCD had steeper eGFR declines compared with adult patients.
Recent clinical trials have demonstrated significant benefits in kidney health, including improved patient outcomes and reduced disease progression. These findings have the potential to revolutionize treatment approaches for patients with kidney disease.
High-impact clinical trials have generated promising results for improving kidney health, according to a recent study. The findings suggest that these trials may lead to better treatment options and improved patient outcomes.
New phase 3 clinical trials show potential for improving kidney health outcomes with targeted therapies, such as pegcetacoplan and semaglutide. These studies have the potential to revolutionize kidney care and treatment.
Researchers have developed a novel gene therapy called PS-002, which targets podocytes and blocks complement activation to treat IgA nephropathy. In mouse models, treatment with PS-002 reduced signs of kidney dysfunction and lowered complement deposition, while in pigs, it resulted in elevated gene expression without safety issues.
A Phase 3 trial of clazakizumab, a monoclonal antibody targeting interleukin-6, failed to demonstrate efficacy in treating chronic active antibody-mediated kidney transplant rejection. The study, which recruited 350 patients, showed no significant improvement in kidney function at week 52.
A phase 2 clinical trial found imlifidase to be more effective than plasmapheresis in reducing donor-specific antibodies by 97% compared to 42%. The investigational drug achieved maximum DSA depletion in 15 hours, outperforming the standard treatment.
A recent study found that GLP-1RA medications are not associated with an increased risk of acute kidney injury (AKI) in patients receiving anti-cancer therapies. Researchers analyzed medical records of 14,783 patients and discovered a lower incidence of AKI among those taking GLP-1RA compared to those without exposure.
Recent phase 3 clinical trials have generated promising results for improving kidney health, including finerenone and semaglutide's effects on kidney parameters. These findings will be presented at ASN Kidney Week 2024.
A novel approach combines 17 biomarkers to identify three distinct health dimensions: systemic inflammation and filtration, tubular function, and tubular damage. Higher tubular damage scores were associated with higher risk of CKD progression, while lower tubular function scores predicted mortality risk.
A recent analysis of clinical trial data reveals that SGLT2 inhibitor canagliflozin reduces major adverse cardiovascular events, hospitalization for heart failure or cardiovascular death, and chronic kidney disease progression in older adults. The effects on safety outcomes are not modified by age.
Chronic kidney disease (CKD) prevalence and mortality rates have increased significantly among women worldwide, with a 2.10% annual percentage change in prevalence and a 3.39% increase in mortality. The study highlights the need for policy interventions and public awareness campaigns to curb the rise of CKD.
Felzartamab induces rapid and durable depletion of galactose-deficient IgA1 and total IgA antibodies in patients with IgA nephropathy. The treatment maintains Gd-IgA1 reduction for up to 9 months off-treatment, offering a potential breakthrough in managing this autoimmune kidney disease.
Researchers analyzed over 16,000 biopsies from nearly 7,000 kidney transplant recipients to uncover key insights into microvascular inflammation. The study found reclassified patients with microvascular inflammation in the absence of antibody-mediated responses displayed an increased risk of graft failure.
A real-world analysis of 3,450 kidney transplant patients treated with SGLT2 inhibitors found significant reductions in kidney transplant rejection (59% less likely), kidney transplant failure (33% less likely), major adverse cardiac events (40% less likely), and mortality risk (44% less likely) over a 3-year period.
A new analysis found that county-level structural racism is a significant determinant of death among individuals with kidney failure. Black patients experienced survival advantages at lower levels of structural racism but disadvantages at higher levels.
Researchers found a positive association between elevated urinary albumin and sub-clinical coronary artery pathology, including microcalcifications, in individuals with type 2 diabetes without symptoms of cardiovascular disease. Microcalcification activity was higher in those with albuminuria, indicating potential kidney damage.
Researchers have created a comprehensive atlas of human fetal kidney development, revealing transitions between different cell states. The study identifies key genes associated with rare genetic diseases and offers insights into the heritability of adult kidney traits.
Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been shown to reduce the risk of sustained decline in estimated glomerular filtration rate and cardiorenal composites by 38% and 23%, respectively. The findings support previously reported benefits of sotagliflozin in reducing cardiovascular events.
Researchers analyzed 43 clinical trials and found that trial participants were less diverse than actual transplant recipients in the US. The study suggests that efforts are needed to improve participant diversity in clinical trials to better reflect real-world patients.
Results from high-impact clinical trials will be presented at ASN Kidney Week 2023, offering potential improvements in kidney-related medical care. The trials bring together leading experts and professionals to exchange knowledge and discuss the latest advances.
A study found that exposure to wildfire smoke and fine particulate matter increased the risk of hospitalization and death among hemodialysis patients by 3% and 5%, respectively. Wildfires pose a significant health risk for vulnerable populations, including those with kidney failure.
A new study investigated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes who also have cancer. The research revealed a higher risk of diabetic ketoacidosis and fracture, but lower risks of acute kidney injury and urinary tract infection compared to another diabetes medication called GLP-1 RA.
Researchers found that vancomycin treatment reduced inflammation in the kidney and increased beneficial bacteria, while polymyxin B showed no significant effect. The study suggests modifying gut microbiota through antibiotic administration may help alleviate hypertensive organ damage.
Researchers have implemented an automated health maintenance tool to prompt primary care physicians to screen for chronic kidney disease in adult patients with type 2 diabetes. The tool has shown higher rates of testing for kidney function screening tests after implementation.
A study found that combining medications can substantially prolong patients' survival free of kidney failure. For a 50-year-old patient, estimated survival was 17.0 years with combination therapy versus 9.6 years with no treatment.
A recent study examines the environmental sustainability practices of dialysis facilities in Australia and New Zealand, revealing multiple areas for improvement. The survey-based study identified opportunities to reduce waste and resource consumption, with only 33% of facilities responding to the survey indicating a lack of prioritizat...
A study published in CJASN found that symptoms related to kidney failure worsened before dialysis but stabilized after initiation. The analysis revealed a significant decrease in symptom number and burden after dialysis, particularly for fatigue and sexual symptoms.
Researchers developed a strategy combining urinary albumin:creatinine ratio (UACR) and glomerular filtration rate (GFR) slope to predict treatment effects on patient outcomes. This approach improved predictions in phase 2 clinical trials with sample sizes of 100–200 patients per arm or follow-up times ranging between 1 and 2 years.
The COVID-19 pandemic has significantly increased the mortality risk of hemodialysis patients, with risks persisting at higher levels for those with confirmed infections. Other patients on dialysis experienced slightly elevated mortality risk during peak pandemic periods.
A recent analysis of COVID-19 cases in four waves found that individuals with chronic kidney disease were more likely to develop severe forms of COVID-19 and experience complications. Pre-existing conditions, including CKD, were consistent clinical predictors of COVID-19 severity across multiple pandemic waves.
Patients with advanced kidney disease may benefit from conservative non-dialytic management over dialysis for hospitalization prevention. Patients of Asian ethnicity show the highest hospitalization rates on early dialysis compared to late dialysis or conservative management. Conservative management underutilized in US due to uncertain...
Research analyzed 350,994 participants and found that higher air pollution concentrations increased the risk of developing chronic kidney disease. Individuals with high air pollution exposure and low genetic risk faced a significantly higher risk of developing CKD compared to those with high genetic risk.